For research use only. Not for therapeutic Use.
Merimepodib（Cat No.:I002524）is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH), a key enzyme involved in purine biosynthesis. By disrupting this pathway, Merimepodib impairs viral replication and has shown efficacy in treating various viral infections, including hepatitis C and respiratory syncytial virus (RSV). Additionally, it has demonstrated potential in cancer treatment by modulating immune responses and suppressing tumor growth. As an antiviral and immunomodulatory agent, Merimepodib holds promise for both infectious disease and oncology applications, especially when combined with other therapeutic strategies for enhanced efficacy.
| Catalog Number | I002524 |
| CAS Number | 198821-22-6 |
| Synonyms | [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate |
| Molecular Formula | C23H24N4O6 |
| Purity | ≥95% |
| Target | HBV |
| Solubility | DMSO: ≥ 31 mg/mL |
| Storage | Store at -20C |
| IUPAC Name | [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate |
| InChI | InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1 |
| InChIKey | JBPUGFODGPKTDW-SFHVURJKSA-N |
| SMILES | COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4 |
| Reference | </br>1:Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination Study Group..Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204. PMID: 19852040 </br>2:Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. Marcellin P, Horsmans Y, Nevens F, Grange JD, Bronowicki JP, Vetter D, Purdy S, Garg V, Bengtsson L, McNair L, Alam J.J Hepatol. 2007 Oct;47(4):476-83. Epub 2007 Jun 21. PMID: 17629590 </br>3:A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. McHutchison JG, Shiffman ML, Cheung RC, Gordon SC, Wright TL, Pottage JC Jr, McNair L, Ette E, Moseley S, Alam J.Antivir Ther. 2005;10(5):635-43. PMID: 16152757 </br>4:Merimepodib (Vertex). Tossing G.IDrugs. 2003 Apr;6(4):372-6. Review. No abstract available. PMID: 12789609 |
